Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37; A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial

Trial Profile

A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37; A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs LL 37 (Primary)
  • Indications Leg ulcer; Varicose ulcer
  • Focus Therapeutic Use
  • Acronyms HEAL LL-37
  • Most Recent Events

    • 20 Oct 2018 Planned number of patients changed from 120 to 159.
    • 01 Oct 2018 According to a ProMore Pharma media release, first patient has been enrolled in this trial.
    • 01 Oct 2018 Status changed from planning to recruiting, as reported in the ProMore Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top